N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase

被引：38

作者：

Connolly, PJ ^{[1
]}

Wetter, SK ^{[1
]}

Beers, KN ^{[1
]}

Hamel, SC ^{[1
]}

Chen, RHK ^{[1
]}

Wachter, MP ^{[1
]}

Ansell, J ^{[1
]}

Singer, MM ^{[1
]}

Steber, M ^{[1
]}

Ritchie, DM ^{[1
]}

Argentieri, DC ^{[1
]}

机构：

[1] RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 1999年 / 9卷 / 07期

关键词：

D O I：

10.1016/S0960-894X(99)00117-1

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Two series of compounds (1 and 2) having structural features of the dual COX/5-LO inhibitor tepoxalin and the 5-LO inhibitor ABT-761 were prepared. Many of these hybrid compounds are potent COX and 5-LO inhibitors; two compounds (la and 2t) inhibit eicosanoid biosynthesis in an ex vivo assay. (C) 1999 Elsevier Science Ltd. All rights reserved.

引用

页码：979 / 984

页数：6

共 50 条

[41] EICOSATETRAENEHYDROXAMATES - INHIBITORS OF 5-LIPOXYGENASE
KERDESKY, FAJ
HOLMS, JH
SCHMIDT, SP
DYER, RD
CARTER, GW
BROOKS, DW
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1985, 190 (SEP): : 29 - MEI
[42] EICOSATETRAENEHYDROXAMATES - INHIBITORS OF 5-LIPOXYGENASE
KERDESKY, FAJ
HOLMS, JH
SCHMIDT, SP
DYER, RD
CARTER, GW
TETRAHEDRON LETTERS, 1985, 26 (18) : 2143 - 2146
[43] Convergent oxygenation of arachidonic acid by 5-lipoxygenase and cyclooxygenase-2
Schneider, C
Boeglin, WE
Yin, HY
Stec, DF
Voehler, M
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (03) : 720 - 721
[44] DESIGN AND SYNTHESIS OF NOVEL STYRYLHETEROCYCLES AS INVITRO AND INVIVO INHIBITORS OF 5-LIPOXYGENASE AND CYCLOOXYGENASE
FLYNN, DL
BELLIOTTI, TR
BOCTOR, AM
CONNOR, DT
KOSTLAN, CR
NIES, DE
ORTWINE, DF
SCHRIER, DJ
SIRCAR, JC
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1988, 196 : 124 - MEDI
[45] Synthesis of pyrazole-containing dual cyclooxygenase/5-lipoxygenase inhibitors.
Connolly, PJ
Wetter, SK
Beers, KN
Hamel, SC
Chen, RHK
Wachter, MP
Ansell, J
Singer, MM
Steber, M
Argentieri, DC
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 214 : 215 - MEDI
[46] Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: Pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea
Adams, JL
Garigipati, RS
Sorenson, M
Schmidt, SJ
Brian, WR
Newton, JF
Tyrrell, KA
Garver, E
Yodis, LA
ChabotFletcher, M
Tzimas, M
Webb, EF
Breton, JJ
Griswold, DE
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (26) : 5035 - 5046
[47] Prevention of thrombosis and vascular inflammation: importance of combined cyclooxygenase and 5-lipoxygenase inhibitors
Hatmi, M
Samama, MM
Elalamy, I
JOURNAL DES MALADIES VASCULAIRES, 2006, 31 (01) : 4 - 9
[48] Synthesis and structure-activity relationships of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives as 5-lipoxygenase inhibitors
Phillips, Oludotun A.
Bosso, Mira A.
Ezeamuzie, Charles I.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, 35 (01) : 1471 - 1482
[49] Asymmetric synthesis of (R)-N-3-butyn-2-yl-N-hydroxyurea, a key intermediate for 5-lipoxygenase inhibitors
Kolasa, T
Stewart, AO
Brooks, CDW
TETRAHEDRON-ASYMMETRY, 1996, 7 (03) : 729 - 736
[50] INVITRO EVALUATION OF 5-LIPOXYGENASE AND CYCLOOXYGENASE INHIBITORS USING BOVINE NEUTROPHILS AND PLATELETS AND HPLC
DANNHARDT, G
LEHR, M
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1992, 44 (05) : 419 - 424

← 1 2 3 4 5 →